Deciphering mitophagic flux in glucocorticoid-induced osteoporosis: a commentary on the SIRT3-ferroptosis axis

This study by Hu et al[1] presents a compelling and mechanistically detailed investigation into the pathogenesis of glucocorticoid-induced osteoporosis (GIOP). The research successfully identifies a novel regulatory axis, SIRT3/mitophagy/ferroptosis, in osteoblasts, offering a fresh perspective on a clinically significant problem. The work is systematic, employing both in vivo and in vitro approaches to build a coherent narrative. However, while the findings are promising and well-supported within the experimental framework, several aspects warrant critical consideration regarding interpretation, clinical translation, and mechanistic depth. The current paper is compliant with the TITAN Guidelines 2025 – governing declaration and use of AI[2]. First, the study interprets PINK1/PARKIN upregulation as “excessive mitophagy.” However, the data cannot exclude an alternative scenario: severe mitochondrial damage triggers a compensatory response that is inefficient or blocked at later stages. While initiation markers and mitophagosomes increase, the critical measure of complete flux to lysosomal degradation is absent. Impaired clearance would cause toxic accumulation of damaged mitochondria, explaining oxidative stress and ferroptosis[3]. This distinction is therapeutically vital: true excess warrants inhibitors like Mdivi-1, whereas a blockade requires enhancing later degradation stages. Future studies using lysosomal inhibitors with GC exposure could clarify the actual nature of the disruption by measuring flux directly. Second, the study’s mechanistic conclusions depend significantly on the specificity of pharmacological tools, which presents a challenge. The designation of Mdivi-1 as a “mitophagy inhibitor” is complicated by its well-established primary action on the mitochondrial fission GTPase Drp1[4]. While inhibiting fission can disrupt mitophagy, Drp1’s role in broader mitochondrial homeostasis means the observed benefits such as reduced ferroptosis and restored osteogenic function may stem from improved overall mitochondrial health rather than solely from mitophagy inhibition. Similarly, the use of Nicotinamide Riboside (NR) as a “SIRT3 agonist” is problematic. As an NAD+ precursor, NR non-specifically enhances all NAD+-dependent enzymes, including other sirtuins and PARPs[5]. Consequently, the rescue effects could be mediated by a general boost in cellular NAD+ metabolism. To solidify the claim of SIRT3’s specific role, future work should employ genetic approaches, such as SIRT3 knockdown, to confirm that the protective effects of NR are indeed abrogated without SIRT3. Third, the study’s exclusive focus on osteoblasts presents a bone remodeling paradox. GIOP involves both suppressed bone formation and enhanced osteoclast resorption. While Mdivi-1 and NR improved bone mass in vivo, the authors attribute this solely to rescued osteoblast function without assessing osteoclast activity. This is a critical gap, as systemic NR administration could directly affect osteoclasts. SIRT3 can enhance osteoclast activity, potentially counteracting anabolic benefits, or suppress it, amplifying the net gain. The study cannot distinguish these contributions. Histomorphometric analysis of osteoclast markers is needed to rule out confounding effects on bone resorption. Forth, the translation of SIRT3 as a therapeutic target requires addressing key clinical challenges. The study’s prevention model, where treatment coincides with glucocorticoid (GC) onset, differs from the clinical reality of treating established osteoporosis. A critical question is whether SIRT3 activation can reverse existing bone loss. Furthermore, systemic administration of NAD+ precursors like Nicotinamide Riboside (NR) lacks tissue specificity, raising safety concerns from chronic, global effects on processes like mitophagy. A targeted delivery system is a necessary next step. Finally, the high-dose GC model’s relevance to common chronic, low-dose therapy is unproven. Future work must test SIRT3 agonism in reversal and chronic low-dose models to validate its therapeutic potential. In conclusion, this study opens a promising new avenue for research. However, the path from this mechanistic discovery to a viable therapeutic strategy for GIOP patients remains long and requires addressing the critical points outlined above.